Investigational drug · Phase 3
AAA817
Also called: [225Ac]Ac-PSMA-617
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "AAA817"
First trial start
2025
Feb 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AAA817", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AAA817" as an intervention, largest first.
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06855277 · 940 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 29, 2028
Drug: AAA817; ARPI and 1 more · For: Prostate Cancer
Sites: Homewood, Alabama; Tucson, Arizona; Orange, California · 106 sites in all
- Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06780670 · 443 participants (planned) · Start Feb 27, 2025 · Primary completion Jun 27, 2028
Drug: Investigators choice of SoC; AAA817 and 2 more · For: Prostate Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; Palo Alto, California · 93 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Multimodal Evaluation of [225Ac]Ac-PSMA-617 Therapy in mCRPC: PET Based Total Tumor Volume, PSA Kinetics, and Blood Biomarkers.
Ebrahimifard A, Bagheri S, Wang Q, et al. · Int J Mol Sci 2026
- Evaluation of [225Ac]Ac-PSMA-617 vis-a-vis Rechallenge [177Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
Agrawal R, Parghane RV, Joshi A, et al. · Prostate 2026
- Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.
Ballal S, Yadav MP, Satapathy S, et al. · Eur J Nucl Med Mol Imaging 2023
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.